Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors-Reference-Cited by-同舟云学术

Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors

Published:2019-12-10 Issue:4 Volume:28 Page:379-385
ISSN:1061-186X
Container-title:Journal of Drug Targeting
language:en
Short-container-title:Journal of Drug Targeting

Author:

Khodabakhsh Farnaz¹,Muyldermans Serge²,Behdani Mahdi³,Kazemi-Lomedasht Fatemeh³^ORCID

Affiliation:

1. Department of Genetics and Advanced Medical Technology, Medical Biotechnology Research Center, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran;

2. Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium;

3. Biotechnology Research Center, Venom and Biotherapeutics Molecules Laboratory, Pasteur Institute of Iran, Tehran, Iran

Publisher

Informa UK Limited

Subject

Pharmaceutical Science

Link

https://www.tandfonline.com/doi/pdf/10.1080/1061186X.2019.1693578

Reference80 articles.

1. The Global Burden of Cancer 2013

2. The anti-angiogenic isoforms of VEGF in health and disease

3. Regulation of Osteogenesis-Angiogenesis Coupling by HIFs and VEGF

4. VEGF and the quest for tumour angiogenesis factors

5. Silver nanoparticles protect human keratinocytes against UVB radiation-induced DNA damage and apoptosis: potential for prevention of skin carcinogenesis

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction Strategy of Functionalized Liposomes and Multidimensional Application;Small;2024-01-22

2. Recombinant antibody fragment therapeutics: Current status and future prospects of scFv, nanobody, and mimotopes;Journal of Drug Delivery Science and Technology;2023-11

3. Protein Corona Attenuates the Targeting of Antitumor Sialyl Lewis X-Decorated Liposomes to Vascular Endothelial Cells under Flow Conditions;Pharmaceutics;2023-06-16

4. Efficient Inhibition of Pathologic Angiogenesis using Combination Therapy of Anti-Epcam and Anti-VEGFR2 Nanobodies;Current Pharmaceutical Design;2023-04

5. Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis;Immunopharmacology and Immunotoxicology;2022-10-12